Dokument: Refinement of intermediate-risk Karyotypes according to the IPSS-R in patients with myelodysplastic neoplasms (MDS)
| Titel: | Refinement of intermediate-risk Karyotypes according to the IPSS-R in patients with myelodysplastic neoplasms (MDS) | |||||||
| URL für Lesezeichen: | https://docserv.uni-duesseldorf.de/servlets/DocumentServlet?id=70373 | |||||||
| URN (NBN): | urn:nbn:de:hbz:061-20250728-121856-0 | |||||||
| Kollektion: | Publikationen | |||||||
| Sprache: | Englisch | |||||||
| Dokumententyp: | Wissenschaftliche Texte » Artikel, Aufsatz | |||||||
| Medientyp: | Text | |||||||
| Autoren: | Nachtkamp, Kathrin [Autor] Schulz, Felicitas [Autor] Kasprzak, Annika [Autor] Strupp, Corinna [Autor] Hildebrandt, Peter [Autor] Pfeilstöcker, M. [Autor] Valent, P. [Autor] Blum, B. [Autor] Giagounidis, A. [Autor] Goetze, K. [Autor] | |||||||
| Dateien: |
| |||||||
| Stichwörter: | IPSS-R, New karyotype risk groups, Intermediate-risk, Prognosis, Myelodysplastic neoplasms | |||||||
| Beschreibung: | MDS patients show a heterogenous prognosis which can be stratified by the IPSS-R in order to derive therapeutic implications. Based on 618 patients with myelodysplastic neoplasms belonging to the cytogenetic intermediate-risk group according to IPSS-R, we show that this group is heterogeneous in terms of overall survival and cumulative risk of AML. The group can be reorganized into subgroups according to their prognostic impact. A small subgroup of patients with isolated -X or der(1;7) can be regarded as very-low-risk patients with a median survival time of 112 months and a cumulative AML progression rate of 9% after 2 years. A larger group of patients with either diverse aberrations of one chromosome or -Y + one additional aberration shows a benign course of the disease with a median survival time of 46 months and a cumulative AML progression rate of 26% after 2 years. A very large group of patients presenting with either + 8, +19, i(17q), + 21, +mar, del(9q), + 8 plus one other aberration, or del(7q) have a poor prognosis with a median survival time of 26 months and a cumulative AML progression rate of 32% after 2 years. In a very small set of patients with trisomy 11 the course of disease was similar to very-high-risk patients with a median survival time of 17 months only and a cumulative AML progression rate of 100% after 2 years. These findings could lead to a refinement of prognostic scoring systems such as the IPSS-R and the IPSS-M. | |||||||
| Rechtliche Vermerke: | Originalveröffentlichung:
Nachtkamp, K., Schulz, F., Kasprzak, A., Strupp, C., Hildebrandt, B., Pfeilstöcker, M., Valent, P., Blum, B., Giagounidis, A., Götze, K., Flatten, V., Dietrich, S., Kobbe, G., Haase, D., Gattermann, N., & Germing, U. (2025). Refinement of intermediate-risk Karyotypes according to the IPSS-R in patients with myelodysplastic neoplasms (MDS). Annals of Hematology, 104(6), 3251–3259. https://doi.org/10.1007/s00277-025-06443-6 | |||||||
| Lizenz: |  Dieses Werk ist lizenziert unter einer Creative Commons Namensnennung 4.0 International Lizenz | |||||||
| Fachbereich / Einrichtung: | Medizinische Fakultät | |||||||
| Dokument erstellt am: | 28.07.2025 | |||||||
| Dateien geändert am: | 28.07.2025 |
